Build the business behind the prescription.

Decide where the business can win

My founder responsibilities spanned payer and network participation, purchasing, inventory, staffing, automation and transaction readiness. Each choice affected the others: entering a therapy category created access and purchasing requirements, while a payer contract changed the margin and cash available to support them. The strategic question was which combination the business could sustain.

A revenue opportunity must be evaluated against reimbursement, acquisition cost, inventory exposure and the work required to support access. The relevant question is the quality and repeatability of contribution, not the size of the prescription alone.

Invest where control changes the outcome

The record includes ScriptPro automation alongside dispensing reliability and a reported throughput improvement. The investment interpretation is broader than labor substitution. Automation has value when it strengthens a workflow whose demand, exception handling and service requirements are understood.

I would assess a build-or-buy decision by the constraint it removes, the degree of control required and the flexibility left afterward. Owning every activity is not a strategy. The business should own capabilities whose quality, economics or learning materially affect its position, and use partners where doing so improves resilience.

Manage cash and concentration together

Growth can consume cash before it produces cash. Inventory commitments, reimbursement timing, payer exposure and operating cost should therefore sit beside the income statement in the leadership review.

My current underwriting lens would stress-test a change in reimbursement, a slower collection cycle and a concentrated referral source. Each can change how much growth the business can safely support even if the headline margin appears unchanged. The case does not contain a reconstructed cash-flow series, so those are decision tests rather than historical financial claims.

Build for transferability

Divestiture readiness tests whether the business can be understood and operated beyond its founder. Documentation, compliance, financial control and dependable execution become part of the asset—not administrative work postponed until a transaction.

The reported journey from formation to $8M+ annualized revenue and strategic divestiture is the operating record. The transferable lesson is to develop growth, margin discipline and diligence readiness together. Revenue alone does not establish transaction value.